Evidence map›Paper›PMID 40609051›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Synaptic Density in Multiple Sclerosis: An In Vivo Study Using [

Amelie Luoma, Markus Matilainen, Jouni Mikael Tuisku, Richard Aarnio, Taru Nikkilä, Sini Laaksonen, Mikko Koivumäki, Eveliina Honkonen, Marjo Nylund, Saara Wahlroos and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Multiple sclerosis: 2026 update.Free neuropathology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Amelie LuomaTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0009-0001-5689-052X
Markus MatilainenTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0000-0002-5597-2670
Jouni Mikael TuiskuTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0000-0003-0965-9365
Richard AarnioTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0000-0002-6420-514X
Taru NikkiläClinical Neurosciences, University of Turku, Turku, Finland.
Sini LaaksonenTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.
Mikko KoivumäkiTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.
Eveliina HonkonenTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0009-0006-4707-7277
Marjo NylundTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0000-0001-6695-5684
Saara WahlroosTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.
Olof SolinTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.
Ming-Kai ChenDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT.
Takuya ToyonagaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-0369-8294
Jussi LehtoTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.
Anniina SnellmanTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0000-0001-6191-0954
Juha O RinneTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0000-0001-6369-0764
Laura M AirasTurku PET Centre, Turku University Hospital, University of Turku, and Åbo Akademi University, Turku, Finland.ORCID 0000-0002-9751-5881

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMultiple sclerosis (MS) is a chronic inflammatory disease coupled with neurodegenerative processes affecting both the white matter and gray matter (GM) in the CNS. Several histopathologic studies have reported a reduction in synaptic density in various areas of the brain. However, this pathologic feature is yet an unexplored entity among people with MS (pwMS). Therefore, we sought to investigate synaptic loss in vivo by quantifying the synaptic vesicle glycoprotein 2A using [

methodsTen pwMS and 8 healthy controls (HCs) underwent high-resolution [

resultsTen pwMS (7 women [70%], median [interquartile range] age, 53 [50-56]) years were compared with 8 HCs (6 women [75%]; age, 51 [50-70] years). PwMS had a significantly lower SV2A availability in the cortical GM (pwMS: mean [SD], V DISCUSSION: Using in vivo [

Indexed as

Cognitive DysfunctionMembrane GlycoproteinsMultiple SclerosisNerve Tissue ProteinsSynapsesAdultCarbon RadioisotopesFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyCarbon RadioisotopesMembrane GlycoproteinsNerve Tissue ProteinsSV2A protein, human

Identifiers

PMID40609051
PMCPMC12227148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.